首页> 美国卫生研究院文献>Molecular Therapy >Cell Cycle Status of CD34+ Hemopoietic Stem Cells Determines Lentiviral Integration in Actively Transcribed and Development-related Genes
【2h】

Cell Cycle Status of CD34+ Hemopoietic Stem Cells Determines Lentiviral Integration in Actively Transcribed and Development-related Genes

机译:CD34 +造血干细胞的细胞周期状态确定慢病毒整合活跃转录和发展相关的基因。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Gene therapy utilizing lentiviral-vectors (LVs) is postulated as a dynamic therapeutic alternative for monogenic diseases. However, retroviral gene transfer may cause insertional mutagenesis. Although, such risks had been originally estimated as extremely low, several reports of leukemias or clonal dominance, have led to a re-evaluation of the mechanisms operating in insertional mutagenesis. Therefore, unraveling the mechanism of retroviral integration is mandatory toward safer gene therapy applications. In the present study, we undertook an experimental approach which enabled direct correlation of the cell cycle stage of the target cell with the integration profile of LVs. CD34+ cells arrested at different stages of cell cycle, were transduced with a GFP-LV. LAM-PCR was employed for integration site detection, followed by microarray analysis to correlate transcribed genes with integration sites. The results indicate that ~10% of integration events occurred in actively transcribed genes and that the cell cycle stage of target cells affects integration pattern. Specifically, use of thymine promoted a safer profile, since it significantly reduced integration within cell cycle-related genes, while we observed increased possibility for integration into genes related to development, and decreased possibility for integration within cell cycle and cancer-related genes, when transduction occurs during mitosis.
机译:假定利用慢病毒载体(LVs)进行基因治疗是单基因疾病的动态治疗选择。但是,逆转录病毒基因转移可能会引起插入诱变。尽管最初估计此类风险极低,但有几篇关于白血病或克隆优势的报道导致对插入诱变的作用机理进行了重新评估。因此,揭示逆转录病毒整合的机制对于更安全的基因治疗应用是必不可少的。在本研究中,我们采用了一种实验方法,该方法可以使目标细胞的细胞周期阶段与LV的整合曲线直接相关。用GFP-LV转导在细胞周期不同阶段停滞的CD34 + 细胞。使用LAM-PCR进行整合位点检测,然后进行微阵列分析以使转录的基因与整合位点相关。结果表明,约10%的整合事件发生在主动转录的基因中,并且靶细胞的细胞周期阶段会影响整合模式。具体而言,胸腺嘧啶的使用促进了安全性,因为它显着降低了与细胞周期相关的基因内的整合,而我们观察到当与胸腺嘧啶脱氧核苷整合时,与细胞发育相关的基因整合的可能性增加,而与细胞周期和癌症相关基因整合的可能性降低。转导发生在有丝分裂期间。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号